487 related articles for article (PubMed ID: 8491280)
41. Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease.
Baker KA; Hong M; Sadi D; Mendez I
Exp Neurol; 2000 Apr; 162(2):350-60. PubMed ID: 10739641
[TBL] [Abstract][Full Text] [Related]
42. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment.
Cenci MA; Tranberg A; Andersson M; Hilbertson A
Neuroscience; 1999; 94(2):515-27. PubMed ID: 10579213
[TBL] [Abstract][Full Text] [Related]
43. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
Decressac M; Mattsson B; Björklund A
Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
[TBL] [Abstract][Full Text] [Related]
44. The site of dopamine formation in rat striatum after L-dopa administration.
Hefti F; Melamed E; Wurtman RJ
J Pharmacol Exp Ther; 1981 Apr; 217(1):189-97. PubMed ID: 7205652
[TBL] [Abstract][Full Text] [Related]
45. Enhanced efficacy of nigral-striatal cotransplants in bilaterally dopamine-depleted rats: an anatomical and behavioral analysis.
Costantini LC; Vozza BM; Snyder-Keller AM
Exp Neurol; 1994 Jun; 127(2):219-31. PubMed ID: 7913445
[TBL] [Abstract][Full Text] [Related]
46. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Rogers JT; Devoto P; Björklund A; Carta M
Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
[TBL] [Abstract][Full Text] [Related]
47. L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset.
Svenningsson P; Gunne L; Andren PE
Neuroscience; 2000; 99(3):457-68. PubMed ID: 11029538
[TBL] [Abstract][Full Text] [Related]
48. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
Chagniel L; Robitaille C; Lebel M; Cyr M
Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
[TBL] [Abstract][Full Text] [Related]
49. Behavioral indices of moderate nigro-striatal 6-hydroxydopamine lesion: a preclinical Parkinson's model.
Fornaguera J; Schwarting RK; Boix F; Huston JP
Synapse; 1993 Feb; 13(2):179-85. PubMed ID: 7680495
[TBL] [Abstract][Full Text] [Related]
50. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
Lebel M; Chagniel L; Bureau G; Cyr M
Neurobiol Dis; 2010 Apr; 38(1):59-67. PubMed ID: 20060905
[TBL] [Abstract][Full Text] [Related]
51. CART modulates the effects of levodopa in rat model of Parkinson's disease.
Upadhya MA; Shelkar GP; Subhedar NK; Kokare DM
Behav Brain Res; 2016 Mar; 301():262-72. PubMed ID: 26771081
[TBL] [Abstract][Full Text] [Related]
52. Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra.
Sengstock GJ; Olanow CW; Dunn AJ; Barone S; Arendash GW
Exp Neurol; 1994 Nov; 130(1):82-94. PubMed ID: 7529713
[TBL] [Abstract][Full Text] [Related]
53. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Winkler C; Kirik D; Björklund A; Cenci MA
Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
[TBL] [Abstract][Full Text] [Related]
54. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.
Fenu S; Pinna A; Ongini E; Morelli M
Eur J Pharmacol; 1997 Feb; 321(2):143-7. PubMed ID: 9063681
[TBL] [Abstract][Full Text] [Related]
55. Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats.
Buck K; Voehringer P; Ferger B
Neuroscience; 2010 Mar; 166(2):355-8. PubMed ID: 20026252
[TBL] [Abstract][Full Text] [Related]
56. L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function.
Espadas I; Darmopil S; Vergaño-Vera E; Ortiz O; Oliva I; Vicario-Abejón C; Martín ED; Moratalla R
Neurobiol Dis; 2012 Dec; 48(3):271-81. PubMed ID: 22820144
[TBL] [Abstract][Full Text] [Related]
57. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
[TBL] [Abstract][Full Text] [Related]
58. Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine.
Czarnecka A; Lenda T; Domin H; Konieczny J; Smiałowska M; Lorenc-Koci E
Brain Res; 2013 Dec; 1541():92-105. PubMed ID: 24129225
[TBL] [Abstract][Full Text] [Related]
59. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
[TBL] [Abstract][Full Text] [Related]
60. Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease.
Kamińska K; Lenda T; Konieczny J; Wardas J; Lorenc-Koci E
Neurochem Int; 2018 Dec; 121():125-139. PubMed ID: 30290201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
